Success Stories: NIW Approved for Human Genetics Researcher Advancing Ophthalmic Genomics

Client’s Testimonial:

“Thank you so much for patiently working on my petition.”

On August 5^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Visiting Fellow in the field of Life Sciences (Approval Notice).

General Field: Life Sciences

Position at the Time of Case Filing: Visiting Fellow

Country of Origin: India

State of Residence at the Time of Filing: Maryland

Approval Notice Date: August 5^th, 2025

Processing Time: 8 days (Premium Processing Requested)

Case Summary:

We are pleased to share the success story of an EB-2 NIW approval granted to a biomedical researcher whose work integrates genomic sequencing, molecular assays, and bioinformatic analyses to uncover genetic variants underlying inherited and age-related eye diseases. The petition demonstrated that her proposed endeavor has both substantial merit and national importance.

Research Focus and Contributions

The petition detailed the client’s research program, which includes:

Identifying and characterizing genetic mutations in cataracts and retinal dystrophies using whole-genome and exome sequencing
Mapping expression quantitative trait loci in lens tissue to pinpoint risk alleles for early-onset vision disorders
Collaborating with international experts to model pathogenic mechanisms in engineered cell and animal systems

Research Impact and Metrics

To illustrate extraordinary ability, the petition assembled key quantitative metrics:

18 peer-reviewed journal articles and 16 abstracts, reflecting a sustained record of high-quality contributions
188 total citations, demonstrating wide adoption of her findings in ophthalmic genetics and related fields
Completed at least 36 invited manuscript reviews for leading journals, confirming her role as a trusted authority in human genetics

Here is an anonymized excerpt from a recommendation letter that underscores the practical impact of his work:

“[Client] is actively engaged in cutting-edge investigations to fill long-standing gaps in our understanding of the genetic basis of blinding diseases. Their work includes identifying and characterizing novel and known mutations in retinal dystrophy families, improving early genetic diagnosis, expanding therapeutic targets, and leading functional studies of mutations implicated in cataract formation and retinitis pigmentosa–associated genes.”

Demonstrating Substantial Merit & National Importance

The petition documented that her integrative genomic work addresses a critical public-health need, improving early diagnosis and personalized treatment of vision-threatening diseases, and aligns with U.S. priorities for reducing healthcare costs and enhancing quality of life.

Well Positioned for Continued Impact

The submission highlighted her Ph.D. training in human genetics, extensive postdoctoral and research-fellow experience, and leadership of multicenter collaborations at a federal research institute. Independent expert testimonials praised her unique ability to translate genetic discoveries into diagnostic and therapeutic strategies, ensuring the ongoing advancement of ophthalmic genomics.

Approval and Outcome

Filed July 28, 2025, under direct premium processing, and approved August 5, 2025, in just 8 days, this NIW approval underscores the United States’ commitment to retaining exceptional talent in biomedical research. NAILG is honored to have guided this client through a seamless NIW process and looks forward to her continued leadership in the field of genomic medicine and vision science.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.